S100A4 and cancer: The contribution of S100A4 to the EMT process has been demonstrated in patients, being particularly highly expressed in the peripheral leading edge of breast cancer [6], and experimentally in a context of transformation of a non-metastatic human prostate cancer cell line, which leads to the cancers’ acquiring invasive properties [7].